BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16544947)

  • 1. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
    Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
    Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of tamoxifen--DNA adducts in leukocytes from breast cancer patients treated with tamoxifen.
    Umemoto A; Monden Y; Lin CX; Abdul-Momen M; Ueyama Y; Komaki K; Laxmi YR; Shibutani S
    Chem Res Toxicol; 2004 Dec; 17(12):1577-83. PubMed ID: 15606132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
    Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
    Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
    Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
    Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
    Hemminki K; Rajaniemi H; Lindahl B; Moberger B
    Cancer Res; 1996 Oct; 56(19):4374-7. PubMed ID: 8813128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
    Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
    Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients.
    Bartsch H; Phillips DH; Nair J; Hewer A; Meyberg-Solomeyer G; Grischke EM
    Carcinogenesis; 2000 Apr; 21(4):845-7. PubMed ID: 10753226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary toremifene treatment for elderly postmenopausal women with breast cancer.
    Hamada N; Ogawa Y; Nishioka A; Kariya S; Yoshida S
    Oncol Rep; 2004 Feb; 11(2):365-70. PubMed ID: 14719069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
    Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
    Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
    Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
    Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving role of toremifene in the adjuvant setting.
    Holli K
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):48-51. PubMed ID: 9165507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
    Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
    Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
    Saeki T; Okita A; Aogi K; Kakishita T; Okita R; Taira N; Ohama Y; Takashima S; Nishikawa K
    Breast Cancer; 2009; 16(2):113-20. PubMed ID: 18936884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen.
    Shibutani S; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
    Chem Res Toxicol; 1999 Jul; 12(7):646-53. PubMed ID: 10409405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.
    Schild LJ; Phillips DH; Osborne MR; Hewer A; Beland FA; Churchwell MI; Brown K; Gaskell M; Wright E; Poirier MC
    Mutagenesis; 2005 Mar; 20(2):115-24. PubMed ID: 15755801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
    Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
    Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.